NeuroModulation Technique (NMT) Autism Study Announcement

The NeuroModulation Technique Autism Study has been completed and the study has been published.

Click here for details and a link to a copy of the published article.

Dr. Robert Weiner is currently recruiting children ages 5 - 10 with a diagnosis of Autism to participate in an international study to determine if NeuroModulation Technique (NMT) is effective in reducing maladaptive behaviors and increasing adaptive behaviors in children diagnosed with autism.

Inclusion Criteria: Qualified participants are those who have received a formal diagnosis of autism from a physician or psychologist using DSM-IV, DSM-IV-TR or ICD-9-CM diagnostic criteria. Parents and/or legal guardian must supply proof of autism diagnosis. Autism (DSM-IV, DSM-IV-R or ICD-9-CM 299.0) must be diagnosed - any other diagnosis such as Pervasive Developmental Disorder (PDD), Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) or Asperger Syndrome is not sufficient for inclusion in this study.

Children must have had their diagnosis of autism for at least one year prior to the date of the application for participation in this study.

Children must not have started any new therapies or stopped any ongoing therapies designed to treat their autism such behavior therapy, speech therapy, physical therapy, sensory integration, dietary modification or dietary supplementation, or any alternative or experimental therapies not mentioned in the 6 months prior to the date of the application for participation in this study.

The purpose of this requirement is to ensure that improvement in autistic symptoms during the course of this study is not due to stopping a therapy that may have caused a worsening of symptoms in the child, and to make sure that improvement seen during the course of this study was not due to a therapy that was recently started prior to receiving NeuroModulation Technique.

During the course of this study, children will be required to continue with any therapies they have been receiving prior to starting the study, and they will be required to not start any new therapies besides NeuroModulation Technique during the course of this study. Children in the study will be allowed to make any medication changes during the course of the study if required by their treating pediatrician.

Parents and/or legal guardians of children in the study must be fluent in English and complete all forms and questionnaires in English (for U.S. and Canadian research sites only)

Exclusion Criteria: Excluded from participating will be children with any of the following medical conditions: cerebral palsy, Down’s syndrome, traumatic brain injury, encephalitis, Lyme disease, cancer, any active infectious disease, endocrine disorder, other mental disorders such as psychotic disorders or other mood disorders including bipolar disorders, or any acute, chronic or unstable medical condition (such as a seizure disorder, Crohn’s disease, asthma, bronchitis, etc.) other than autism for which the child has been receiving treatment, medication and/or therapy.

Also excluded from the study are children who have undergone chelation therapy in the past or are currently undergoing chelation therapy, and children who have displayed significant self-injurious behavior (children who have caused visible harm to themselves.)

Children with a history of mild to moderate food or airborne allergies, sensitivities, or mild digestive problems are eligible to participate in the study.

If you are not sure whether or not your child is eligible due to a medical condition that is not listed above, please have your participating NMT researcher contact the Study Chair, Dr. Robert Weiner, to see if your child will qualify to be in the study.

In order to participate in the study, children must not have received any previous NeuroModulation Technique treatment.